-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, V23LbmBxKZpcFeM1nvPCSBDsPHEPboTkcF6uJaDC3v24PR15H8bs1VPoXzC5qjWu ownxXqLwb7UqzFAMdzZVYA== 0001193125-04-140332.txt : 20040813 0001193125-04-140332.hdr.sgml : 20040813 20040813145508 ACCESSION NUMBER: 0001193125-04-140332 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20040813 ITEM INFORMATION: Other events ITEM INFORMATION: Financial statements and exhibits FILED AS OF DATE: 20040813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERISOURCEBERGEN CORP CENTRAL INDEX KEY: 0001140859 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 233079390 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-16671 FILM NUMBER: 04973733 BUSINESS ADDRESS: STREET 1: 1300 MORRIS DRIVE, SUITE 100 CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 BUSINESS PHONE: 6107277000 MAIL ADDRESS: STREET 1: 1300 MORRIS DRIVE, SUITE 100 CITY: CHESTERBROOK STATE: PA ZIP: 19087-5594 8-K 1 d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 13, 2004

 


 

AmerisourceBergen Corporation

(Exact name of Registrant as specified in its charter)

 


 

Delaware   1-16671   23-3079390

(State or Other Jurisdiction of

Incorporation or Organization)

  Commission File Number  

(I.R.S. Employer

Identification Number)

 

1300 Morris Drive

Chesterbrook, PA

  19087
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (610) 727-7000

 

N/A

(Former name or former address, if changed since last report.)

 



Item 5. Other Events and Regulation FD Disclosure.

 

On August 13, 2004, AmerisourceBergen Corporation (the “Registrant”) issued a news release announcing that the Registrant’s Board of Directors authorized the Registrant to repurchase up to $500 million of its outstanding shares of common stock subject to market conditions. In the news release, the Registrant also provided its preliminary view on operating revenue and net income, excluding special items, for fiscal 2005. A copy of the news release is filed as Exhibit 99.1 to this report and incorporated herein by reference.

 

Item 7. Financial Statements and Exhibits.

 

  (c) Exhibits.

 

  99.1     News Release dated August 13, 2004


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

AMERISOURCEBERGEN CORPORATION

Date: August 13, 2004

  By:  

/s/ Michael D. DiCandilo


    Name:  

Michael D. DiCandilo

    Title:  

Senior Vice President and Chief Financial Officer

EX-99.1 2 dex991.htm NEWS RELEASE News Release

Exhibit 99.1

 

LOGO

 

 

News Release

 

AmerisourceBergen Corporation

P.O. Box 959

Valley Forge, PA 19482

 

Contact:   Michael N. Kilpatric
    610-727-7118
    mkilpatric@amerisourcebergen.com

 

AMERISOURCEBERGEN BOARD OF DIRECTORS AUTHORIZES

$500 MILLION SHARE REPURCHASE

 

Company Expects to Return to its Long-Term Diluted Earnings Per Share Growth Goal

Of 15 Percent or Higher In the Fourth Quarter of Fiscal 2005

 

VALLEY FORGE, Pa. August 13, 2004 – AmerisourceBergen Corporation (NYSE: ABC), a leading pharmaceutical services company, today announced that its Board of Directors has authorized the Company to repurchase up to $500 million of its outstanding shares of common stock subject to market conditions. In early August, the Company’s senior credit facility was amended to allow this common stock repurchase program. As of July 31, 2004, the Company had approximately 112 million common shares outstanding.

 

The Company will repurchase the shares from time to time for cash in open market transactions in accordance with applicable federal securities laws. The Company will hold any repurchased shares as treasury shares, which will be available for general corporate purposes.

 

“Repurchasing our shares makes sense given AmerisourceBergen’s strong cash flow and the positive impact on diluted earnings per share growth in fiscal 2005,” said R. David Yost, AmerisourceBergen’s Chief Executive Officer. “Recognizing that we are only part way through our planning cycle and will provide formal fiscal 2005 earnings guidance when we release our fiscal 2004 results in early November 2004, our preliminary view is that operating revenue and net income, excluding special items, for fiscal 2005 will be roughly flat in comparison to fiscal 2004, but our share repurchase program will provide for diluted earnings per share growth, excluding special items, in fiscal 2005. Our current view reflects the impact of the Veterans Administration and AdvancePCS account losses and the potential impact on our physician customers from the newly proposed Medicare drug reimbursement regulations.”


Yost added, “With the pharmaceutical industry expected to grow in the low double digits in 2005, we continue to expect to return to our long-term goal of diluted earnings per share growth of 15 percent or higher in the fourth quarter of fiscal 2005, following the anniversary of the above account losses.”

 

About AmerisourceBergen

 

AmerisourceBergen (NYSE:ABC) is one of the largest pharmaceutical services companies in the United States. Servicing both pharmaceutical manufacturers and healthcare providers in the pharmaceutical supply channel, the Company provides drug distribution and related services designed to reduce costs and improve patient outcomes. AmerisourceBergen’s service solutions range from pharmacy automation, bedside medication safety systems, and pharmaceutical packaging to pharmacy services for skilled nursing and assisted living facilities, reimbursement and pharmaceutical consulting services, and physician education. With more than $47 billion in annualized operating revenue, AmerisourceBergen is headquartered in Valley Forge, PA, and employs more than 14,000 people. AmerisourceBergen is ranked #22 on the Fortune 500 list. For more information, go to www.amerisourcebergen.com.

 

FORWARD-LOOKING STATEMENTS

 

This news release may contain certain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. Forward-looking statements may include statements addressing AmerisourceBergen’s future financial and operating results.

 

The following factors, among others, could cause actual results to differ materially from those described in any forward-looking statements: competitive pressures; the loss of one or more key customer relationships; customer insolvencies; changes in customer mix; changes in pharmaceutical manufacturers’ pricing and distribution policies or practices; regulatory changes; changes in U.S. government policies (including changes in government policies pertaining to drug reimbursement); changes in market interest rates; and other economic, business, competitive, regulatory and/or operational factors affecting the business of AmerisourceBergen generally.

 

More detailed information about these factors is set forth in AmerisourceBergen’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal 2003.

 

AmerisourceBergen is under no obligation to (and expressly disclaims any such obligation to) update or alter any forward looking statements whether as a result of new information, future events or otherwise.

 

###

GRAPHIC 3 g7020870208_1.jpg GRAPHIC begin 644 g7020870208_1.jpg M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T- M#AT5%A$8(Q\E)"(?(B$F*S7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V:BBB@`HH MHH`****`(;N=K:V>5())W`^6./JQ]/;ZUPNJ:-XJ\13,M[XAM-*C)P+.VD+% M?9B",FO0*X/XC^#?[7M!JFF6I;4(2`ZQCYID_J1_C710DE*VWF8UDW&^_D(?#EU]FNWDNHHVVR6]UG>OL">0: MIZ/XO\0>&;ORA/*R1G$EIA)RCI62<7U.&*4M:3L^QU%EXEAU?P\VK:/`UXRCYK;>%<,.J_7^ M= M>+=Z!\3;1K2>)=/UN)3Y;'DG'H?XE]CR*Y?P=>7GA/QTEA>`QB23[-<)G@Y^ MZ?SP<^AJS=Z-I6J`ZUX)NY([JV/G/8.<2ICG([A=>/A[Q'"@6YN M9!;7*K_SU1A_//Y8KUXI6<%\+Z/HSS)-W4NJZ]S/\<6(T[Q[=)`-OF2I,H'8 MM@_SS7>>-'4^-_"2>D%%%% M`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!52/5=.EOGL M([ZW>[3.Z!95+K]5SFDU?4H='TB[U*X.(K6)I&]\#I^/2OGO27U30]0TCXB7 MCL8M0U&59AC^`G#'\07Q_NT`?2%%,,T0@,YD41!=Y:`->BJ$FN:3#I@U.34K5;(C(N#,NP_0YQ2Z7K6 MEZW"TVEZA;WB*<,89`VT^^.E`%ZN4^(=[=P^&I;*PM+BXN+W]W^YC+;$_B)Q M[07<)XWPR!QG\*J M$N62E8F4>:+1X!:Z1XCLKJ.ZM=-U"&:)MR.D#`@_E76VD&HW*)>MI,UNT=T+ MQXG@8()]A7(&,[2=K8'N*]+_`.$@T;[))=_VM9?9XGV22_:%VJW]TG/7VJ2+ M6-,GGAMXM0MGFN(Q+#&LJEI$(R&`SDC'>NR>,OCK$&G3:9I. MDZEMNF+WM[);,);ICU&,?*GMU/>JGA30]7@\5Z7+-I=Y'&ERA9V@8!1GJ3BO M9=4\3:'HLBQ:GJUI:2-R$EE`;'KCK5NQU"RU.W%S87<-U"W22%PZ_F*/KC46 ME'07#P-ME6*0,8V]&QT/%$VHV-O>0V0!Y/H.IH`LT51_MS2=EP_\`:=GMM&VW#>>N(F]&YX/!Z^E*=9TM M=,74VU"V6R896X:4",CV;IVH`NT5DZ;XIT#6)S!INL6=U*/^6<U:Y^S:?K5EO.OBQ9V^H_$#PE972>9!<2".1,D;E,B@C(H`] M&_X2OP[_`-![3O\`P*3_`!K0M;RUO8O.M+F*XC_OQ.&'YBN1_P"%1^"/^@-_ MY,2?_%5Q8TZ/P#\8]+TWP_-*+/447S[5I"P`8L#GZ8W#/-`'M%%4M2UC3=&A M$VIW]O9QG@--(%S],]:CTO7]'UM6.EZE;7FS[PAE#%?J.HH`T:*IG5],$]Q` M=0M1+:KNG0S+NB'JPSP/K38];TF73FU&/4K5K-"0UP)E\L$=?FSB@"]1618> M+/#VJ2O%8ZU97#H"S*DRY`'4X]*O6VHV-Y:&\M;R">V&:C8ZIH` MLT5CS>+?#MOJ/]G3:W8I=[MOE-.NX'T/H?:MB@#R[XYZ_P#8]`M=#B?$NH2; MY`.OEK_BV/R-$M2^'8\,6EKJ"O;PH+=W@``=.Y^;OSGZUK^'(+WQI M\7+G7K^UE2PTQ66U\V,J&&2$ZCW+?E7K/V>$_P#+%/\`OD4`<'X)U[^WOA)* MTC[I[.TEMIJV*WT\SN@\XDK&BL1A1GCG)S M[U!H-G>>%?%_BSPZ+6TFTF2>2W4G9E59N!]4'YFMCX=6UQ#XW\9R2P2QI)>`HSH0 M&&Y^A/6H]9TZ2\^-UF)+>5K672Y(I)`AVCP'!'K].!5S1=:T73_`(J:?+X0$\6FZF!#>6QA9$5CD`@' MWP?;GUK3\+ZS-\,5N?#GB33+I[1)FDL[ZW@\Q)%/8_S_`!-;VB^(->\6>+8; MG2[6;3O#=LA\U[FW56NG_P!G(R.W3T/K0!QWPT\#Z;XI_M6ZUDRW%K;WKI%: M"1E3>?O.<$S0>=&4R<8SV^GTXQ71>%[?P_9Z]JGB3PGK4!TQ;-GGT MJ-6!#`9W8/(&1Z=R*;IOC/5?"]S?:1X]L[R\4S%K:]CM@\*XD>+R1L:KQ@`\=<_0`5'XDT^W^'_P`0M!U30XQ:6FJR_9KNUCXC M;D#(';[V?J*3POK%U\+OM?AWQ%I]X]B)VEL[ZWB,B.I[''3U^N:E;[;\3?&^ ME7\.G7-IH&COYOG7*;#.^0<`?4+^&?I0!;^%0QXB\9_]A+_V9Z3QC_R63PA_ MN/\`^S5DV&MW'PT\:^((]7TF]GLM4N/M$%S;Q[L\L1Z`_>P><@BF2:IJOB?X MJ^&]6?1;NRTY=RVYFC.YEPV6;^[DGCZ4`5_"/@ZQ\5^-?%1U5Y9+&UU!S]E2 M0JLDA=\,V/0`_G5RUT*Q\1_%"3PU+$PT'PY;_N;(N2K,<$DY.3RY_``5M?#& MVN(/$WC)YH)8EDU'*%T*AANDY&>M5=>M=3\$?$>7Q?:Z?/?Z5J,7EWBVZ[GB M/'./JH/YCB@#8\4_#'2M6LX7T.&WT;4K>17AN8(]F`#R"%QGVKC/'&JVTWQ` MTO1O%EU)+IFFVJ27*01L1<3%GTS47B'1-:\)>(](\7V\,VM""T6UU,*-TCX&#(![_I@9ZT` M8'C'5?AYJ6B,V@VLEAJMMA[66WLFBR0>A(`_/L:@\57NH>);KP#8%WX^HS78:I\26UFR^P>#=)OYM5N"%1Y+7:D'JS$\?TK$^(::KIG MB#P??7D$^ISV"B6Z>VAP'974D#`P.G%`&T?`?Q`(Q_PL*7_OVW^-_# MOXEVA\2B/57U4A(=29V9XR3MSS]0#['@UTG_``N1?^A1UG_OW6))%X@^*/C3 M2[R;1)]*TC3'#E[@$%N0QZ@9)P!@=*`,^+Q#X-]5O;G3;B\T'6'\[S[>/>8'R3@CZL?J,?2KL_C'5O%NJ65AX,L[FUM MUE#7NH7-J`BI_=`8')_7I0!@6_AFW\6_&+Q!;7LTJV"(DTT,;E?.^5-JDCMD MY_"I]1\-:=J'Q'T_P/;QO;Z%80->26RR,?,=N3DDY_NCV&<5M^%;:XC^,?BJ M=X)5BDA0)(R$*WW.AZ&H_&^GZMX>\;V/CC2K&2_@2'R+Z"(9?;SR!]#^!44` M:'BOX<>'9?#=W)INFPZ?>6T#203VPV,&4$X)'4'ISZUY5_:WE?#KPYHDUQ+; MV%]?3/>/$"6,:N!C`Z]2<>PKT#6_B+-XFT2ZTSPOH^H-=3P.)I[F+RX[9,?, M2'=2U'X;:'KNBP_:+_`$:^EE$&,F5-X)`]3E1QZ9H`T]2U3X3W MNA/IL.GO;L(RL4\=BXD1L<-NQD\^O6N;U#5+W7/AAHMM>2R>=:ZO]E25P=VW M9E3^&)/0GTS_P#JK!\8V/B:;P;X=.NA MKK46U199$AA'[E<'"G:,<=S[XH`W_$GPU\*V'@74VBTU3A=CDX]N
-----END PRIVACY-ENHANCED MESSAGE-----